Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus TRIPROLIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus TRIPROLIDINE HYDROCHLORIDE.
BENYLIN vs TRIPROLIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Competitive antagonist of histamine H1 receptors; inhibits histamine-mediated vasodilation, increased capillary permeability, and bronchoconstriction in allergic reactions.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
2.5 mg orally every 4-6 hours as needed; maximum 10 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life approximately 3–4 hours in healthy adults; prolonged in renal impairment (up to 12 hours).
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Renal (primarily as metabolites; ~70% recovered in urine within 24 hours, <5% unchanged). Fecal elimination is minor.
Category C
Category A/B
Antihistamine
Antihistamine